(2R)-2-(2-吡啶基)-1-丙醇 | 194228-34-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: (2R)-2-(2-吡啶基)-1-丙醇
• 英文名称: (R)-2-(pyridin-2-yl)propan-1-ol
• 英文别名: (2R)-2-pyridin-2-ylpropan-1-ol
• CAS: 194228-34-7
• 化学式: C₈H₁₁NO
• 分子量: 137.181
• InChiKey: OXZXELXVPQSDGR-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2R)-2-(2-吡啶基)-1-丙醇 在 吡啶 、 copper(l) iodide 作用下， 反应 8.17h， 生成 (+)-(S)-2-(1-methylpropyl)pyridine
  参考文献：
  名称：

  Enzyme catalysed asymmetrization of pyridyl substituted 1,3-propanediols and of the corresponding diacetates

  摘要：

  2-(4-pyridyl)- and 2-(2-pyridyl)-1,3-propanediols 1 and 4 were prepared and asymmetrized by enantioselective acetylation in organic solvent catalysed by hydrolytic enzymes, the best being supported pig pancreatic lipase, to give new valuable heterocyclic chiral building blocks. The asymmetrization of diacetate 6, catalysed by pig pancreatic lipase is also described. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0957-4166(97)00218-8
• 作为产物：
  描述：

  (R)-3-(acetoxy)-2-(2-pyridyl)propan-1-ol 在 咪唑 、 氢氧化钾 、 四丁基氟化铵 、 三乙基硼氢化锂 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 7.67h， 生成 (2R)-2-(2-吡啶基)-1-丙醇
  参考文献：
  名称：

  Enzyme catalysed asymmetrization of pyridyl substituted 1,3-propanediols and of the corresponding diacetates

  摘要：

  2-(4-pyridyl)- and 2-(2-pyridyl)-1,3-propanediols 1 and 4 were prepared and asymmetrized by enantioselective acetylation in organic solvent catalysed by hydrolytic enzymes, the best being supported pig pancreatic lipase, to give new valuable heterocyclic chiral building blocks. The asymmetrization of diacetate 6, catalysed by pig pancreatic lipase is also described. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0957-4166(97)00218-8

文献信息

• Photoenzymatic Hydrogenation of Heteroaromatic Olefins Using ‘Ene’‐Reductases with Photoredox Catalysts
  作者：Yuji Nakano、Michael J. Black、Andrew J. Meichan、Braddock A. Sandoval、Megan M. Chung、Kyle F. Biegasiewicz、Tianyu Zhu、Todd K. Hyster

  DOI：10.1002/anie.202003125

  日期：2020.6.22

  selective catalysts for the asymmetric reduction of activated alkenes. This function is, however, limited to enones, enoates, and nitroalkenes using the native hydride transfer mechanism. Here we demonstrate that EREDs can reduce vinyl pyridines when irradiated with visible light in the presence of a photoredox catalyst. Experimental evidence suggests the reaction proceeds via a radical mechanism where

  黄素依赖性“烯”还原酶（ERED）是用于不对称还原活化烯烃的高选择性催化剂。但是，使用天然氢化物转移机制，该功能仅限于烯酮，烯酸酯和硝基烯烃。在这里，我们证明当在光氧化还原催化剂存在下用可见光照射时，EREDs可以还原乙烯基吡啶。实验证据表明，反应是通过自由基机理进行的，其中乙烯基吡啶在溶液中还原为相应的中性苄基。DFT计算显示该自由基是“动态稳定的”，这表明该自由基具有足够长的寿命，可以扩散到酶的活性位点以进行立体选择性氢原子转移。这种减少机制与本地机制不同，
• Pladienolide Pyridine Compounds and Methods of Use
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US20150329528A1

  公开（公告）日：2015-11-19

  The present invention provides novel pladienolide pyridine compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.

  本发明提供了新型的pladienolide吡啶化合物，包含这些化合物的药物组合物，以及将这些化合物用作治疗剂的方法。这些化合物可能在治疗癌症方面有用，特别是对于那些已知靶向剪接体和其中突变的药物在治疗中有用的癌症。
• NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF
  申请人：FUJIWARA Hideyasu

  公开号：US20130116430A1

  公开（公告）日：2013-05-09

  An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl group, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R 3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R 4 and R 5 each independently represent a hydrogen atom; and R 2 and R 4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

  本发明的目的是提供一种具有优异的Syk抑制活性的化合物和制药组合物。本发明提供了一种由以下式(I)表示的烟酰胺衍生物（其中R1表示卤素原子；R2表示C1-12烷基、C2-12烯基、C2-12炔基、C3-8环烷基、芳基、芳基-C1-6烷基或杂环基，每种均可选地具有至少一个取代基；R3表示芳基或杂环基，每种均可选地具有至少一个取代基；R4和R5各自独立地表示氢原子；且R2和R4可以与它们结合的氮原子一起形成具有至少一个取代基的环状氨基团）或其盐，并且用于治疗Syk相关疾病的制药组合物包括该烟酰胺衍生物或其盐。
• [EN] A SOLID STATE FORM OF PLADIENOLIDE PYRIDINE COMPOUNDS AND METHODS OF USE<br/>[FR] FORME D'ÉTAT SOLIDE DE COMPOSÉS DE PLADIÉNOLIDE-PYRIDINE ET PROCÉDÉS POUR LEUR UTILISATION
  申请人：EISAI R&D MAN CO LTD

  公开号：WO2017087667A9

  公开（公告）日：2017-10-12
• WO2019232433A5
  申请人：——

  公开号：WO2019232433A5

  公开（公告）日：2022-06-06